The limits and challenges of antiobesity pharmacotherapy
- 15 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (11), 1319-1328
- https://doi.org/10.1080/14656566.2020.1748599
Abstract
Introduction: Pharmacotherapy is a useful adjunct when patients with obesity are unable to achieve adequate benefit from lifestyle interventions. Areas covered: This review covers the history of antiobesity drugs, efficacy, and risks of currently approved drugs, limits of their usefulness in clinical practice, gaps in knowledge, methodological limitations of clinical trials, and reasons for underutilization. Expert opinion: In randomized controlled trials, currently approved antiobesity drugs have yielded an average weight loss ranging from approximately 3% to 9% relative to placebo at 1 year. Inadequate inclusion of racial and ethnic minorities and men, and high dropout rates in clinical trials limit generalizability of these findings to clinical practice. Weight loss achieved with antiobesity drugs is generally associated with lowered glycemia, but improvements in blood pressure and lipid measures tend to be marginal. There is limited evidence for sustained weight loss beyond 1 year and for safety and efficacy of antiobesity drugs in children and adolescents, and in post-bariatric surgery patients. None have demonstrated reduction in major adverse cardiovascular events or other significant disease outcomes. Limited health insurance coverage and negative perceptions of physicians have hindered the utilization of antiobesity drugs.Keywords
Funding Information
- National Institutes of Health (U01DK048377)
This publication has 82 references indexed in Scilit:
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- A Two-Year Randomized Trial of Obesity Treatment in Primary Care PracticeThe New England Journal of Medicine, 2011
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsThe New England Journal of Medicine, 2010
- Combination therapy for obesity and metabolic diseaseCurrent Opinion in Endocrinology, Diabetes and Obesity, 2009
- Missing Data in Randomized Clinical Trials for Weight Loss: Scope of the Problem, State of the Field, and Performance of Statistical MethodsPLOS ONE, 2009
- Combination pharmaceutical therapies for obesity.Expert Opinion on Pharmacotherapy, 2009
- Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related RisksCirculation, 2006
- Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric SurgeryThe New England Journal of Medicine, 2004
- Binge eating disorder and obesityInternational Journal of Obesity, 2001
- A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve RegurgitationThe New England Journal of Medicine, 1998